Literature DB >> 24920410

Impact of rotational atherectomy on heavily calcified, unprotected left main disease.

Hiroto Yabushita1, Kensuke Takagi, Satoko Tahara, Yusuke Fujino, Takayuki Warisawa, Hiroyoshi Kawamoto, Yusuke Watanabe, Satoru Mitomo, Kenichi Karube, Takahiro Matsumoto, Tomohiko Sato, Toru Naganuma, Tsuyoshi Kobayashi, Hisaaki Ishiguro, Keiko Fukino, Naoyuki Kurita, Shotarou Nakamura, Koji Hozawa, Sunao Nakamura.   

Abstract

BACKGROUND: There is little data on percutaneous coronary intervention (PCI) using rotational atherectomy (Rota) for severely calcified unprotected left main (ULM) lesions. METHODS AND
RESULTS: Between January 2005 and August 2011, 64 consecutive patients who underwent drug-eluting stent implantation using Rota were retrospectively evaluated. Of these, 54.7% and 20.3% patients had diabetes and were undergoing hemodialysis (HD), respectively. The mean EuroSCORE and SYNTAX score was 5.6 and 35.4, respectively. Procedural success, defined as residual stenosis <30%, was achieved in 95.3% of patients without fatal complications. Periprocedural myocardial infarction occurred in 7.8% patients. At the 1-year follow up, cardiac death was observed in 6.3% of patients, and target lesion revascularization (TLR) and TLR in the main branch (TLR-MB) were required in 18.8% and 10.9% patients, respectively. Optimal stent expansion was achieved in the majority of 33 patients with available intravascular ultrasound (IVUS) data. However, 5 of 9 HD patients who underwent IVUS required TLR-MB despite optimal stent expansion. The rate of TLR-MB was significantly lower in the non-HD patients than in the HD patients (2.1% vs. 46.2%; P=0.003).
CONCLUSIONS: PCI using Rota for calcified ULM lesions might guarantee high procedural success and a low complication rate. Although acceptable results were obtained at the 1-year follow up for non-HD patients, the rate of TLR-MB was considerably high for HD patients despite optimal stent expansion.

Entities:  

Mesh:

Year:  2014        PMID: 24920410     DOI: 10.1253/circj.cj-13-1426

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Comparison of mid-term clinical outcomes between on-label and off-label use of rotational atherectomy.

Authors:  Takayuki Mori; Kenichi Sakakura; Hiroshi Wada; Yousuke Taniguchi; Kei Yamamoto; Yusuke Adachi; Hiroshi Funayama; Shin-Ichi Momomura; Hideo Fujita
Journal:  Heart Vessels       Date:  2016-10-05       Impact factor: 2.037

Review 2.  Rotational atherectomy of calcified coronary lesions: current practice and insights from two randomized trials.

Authors:  Abdelhakim Allali; Mohamed Abdel-Wahab; Karim Elbasha; Nader Mankerious; Hussein Traboulsi; Adnan Kastrati; Mohamed El-Mawardy; Rayyan Hemetsberger; Dmitriy S Sulimov; Franz-Josef Neumann; Ralph Toelg; Gert Richardt
Journal:  Clin Res Cardiol       Date:  2022-04-28       Impact factor: 5.460

Review 3.  The Current State of Left Main Percutaneous Coronary Intervention.

Authors:  Harshith R Avula; Andrew N Rassi
Journal:  Curr Atheroscler Rep       Date:  2018-01-17       Impact factor: 5.113

4.  Outcomes of coronary rotational atherectomy in patients with reduced left ventricular ejection fraction.

Authors:  Hui-Ping Zhang; Ying Zhao; Hu Ai; Hui Li; Guo-Dong Tang; Nai-Xin Zheng; Fu-Cheng Sun
Journal:  J Int Med Res       Date:  2019-12-27       Impact factor: 1.671

5.  Intravascular Lithotripsy as a Novel Treatment Method for Calcified Unprotected Left Main Diseases-Comparison to Rotational Atherectomy-Short-Term Outcomes.

Authors:  Piotr Rola; Jan Jakub Kulczycki; Adrian Włodarczak; Mateusz Barycki; Szymon Włodarczak; Marek Szudrowicz; Łukasz Furtan; Artur Jastrzębski; Maciej Pęcherzewski; Maciej Lesiak; Adrian Doroszko
Journal:  Int J Environ Res Public Health       Date:  2022-07-25       Impact factor: 4.614

Review 6.  Percutaneous Left Main Coronary Intervention: A Review of Plaque Modification in Left Main Percutaneous Coronary Intervention.

Authors:  Chirag A Shah; Steven E Pfau
Journal:  J Clin Med       Date:  2018-07-23       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.